Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Oslo – page 22

527 clinical trials in Oslo, Norway across 9 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Oslo at a glance
527
clinical trials
  • Research sites9
Type of trial
Recruitment status
Quick filters

527 trials in Oslo

Open in trial search

Neoplasm

Recruiting

Study on Long-Term Safety of BI 907828 for Patients with Solid Tumors Who Previously Participated in a Study with This Medicine

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Acute lymphocytic leukaemia+4

Recruiting

Study of Dasatinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with MAPK/SRC Pathway Mutation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Dasatinib
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Colitis ulcerative

Recruiting

Study on the Effects of Filgotinib for Children and Teenagers with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Renal transplant

Not yet recruiting

Effect of antimicrobial drugs on tacrolimus and mycophenolate mofetil pharmacokinetics in kidney transplant recipients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Oslo University Hospital HF

Ovarian cancer

Not yet recruiting

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Not yet recruiting

Phase II Randomized Trial of Adjuvant Durvalumab Immunotherapy After Neoadjuvant Chemoimmunotherapy in Patients With Resectable Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Oslo University Hospital HF

Coronary artery disease

Not yet recruiting

Continuing vs Stopping Acetylsalicylic Acid in Elderly Patients with Chronic Coronary Syndrome (Secondary Prevention): A Randomized Trial

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Vestre Viken HF

Renal transplant

Not yet recruiting

AUC‑targeted tacrolimus dosing in kidney transplant recipients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Oslo University Hospital HF

Chronic graft versus host disease

Not yet recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Pulmonary embolism

Not yet recruiting

Reduced-dose versus full-dose alteplase for high-risk acute pulmonary embolism patients: a randomized multicenter trial

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:University Of Gothenburg

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Oslo

What the registry says about research in the country

01 Respiratory Medicine

Clinical trials focusing on pulmonary conditions and respiratory health, including studies on idiopathic pulmonary fibrosis and respiratory syncytial virus prevention in children.

  • IPF Treatment Evaluation
  • RSV Prevention Studies
  • Chronic Wet Cough Research

Innovative therapies being tested to improve lung function and patient outcomes.

02 Cardiovascular Research

Studies examining heart conditions and vascular health, with particular focus on heart failure and cardiovascular disease prevention.

  • Heart Failure Imaging Studies
  • Cardiovascular Disease Prevention
  • Hypovolemia Management

Advanced imaging techniques and therapeutic interventions being evaluated for cardiac conditions.

03 Oncology Studies

Comprehensive research into various cancer treatments, including trials for gastric, esophageal, and rare cancers.

  • Advanced Solid Tumors
  • Targeted Cancer Therapies
  • Multiple Myeloma Treatment

Novel therapeutic approaches combining immunotherapy with conventional treatments.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.